Alexandria Center of Life Sciences
430 E. 29th Street
6 articles with Gotham Therapeutics
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Gotham Therapeutics Establishes Advanced Oncology Profiling Cascade with ProQinase to Progress its Portfolio of Epitranscriptomic Drug Candidates
Gotham’s pipeline covers the entire reader-writer-eraser paradigm with three lead programs advancing in parallel through preclinical discovery
Gotham Therapeutics and Mercachem Announce Progress in Compound Library Development Tailored for Epitranscriptomic Drug Discovery
Research led to a collection of over 2,000 analogues and over 80 distinct chemotypes displaying an up to 1,000-fold increased affinity to epitranscriptomic targets.
Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration
Completion of Gene-to-Lead phase for first discovery project targeting METTL3/METTL14 complex.
Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, today announced the appointment of Carlo Incerti, M.D., Ph.D. as an independent Board Member.
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.